Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1

Conditions

Melanoma 1486Lymphoma, T-Cell, Cutaneous 313Skin Neoplasms 268Keratosis, Actinic 249Mycosis Fungoides 224Sezary Syndrome 216Lymphoma, Non-Hodgkin 206Leukemia, Lymphocytic, Chronic, B-Cell 200Lymphoma, Large B-Cell, Diffuse 198Lymphoma, Follicular 196Neoplasms 194Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Lymphoma, B-Cell, Marginal Zone 192Lymphoma, Mantle-Cell 191Hodgkin Disease 191Carcinoma, Basal Cell 190Breast Neoplasms 185Burkitt Lymphoma 184Lymphoma 182Lymphoma, Large-Cell, Immunoblastic 177Carcinoma, Non-Small-Cell Lung 150Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 140Lymphoma, Large-Cell, Anaplastic 137Multiple Myeloma 133Carcinoma, Renal Cell 128Immunoblastic Lymphadenopathy 126Uveal Melanoma 125Neoplasm Metastasis 120Leukemia, Myeloid, Acute 113Waldenstrom Macroglobulinemia 103

Interventions

Brentuximab Vedotin 2Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphomatoid Papulosis × Dermatologic × Clear all
NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡